VERSANT VENTURES BACKS APREA AB CONTINUING GLOBAL INVESTMENT STRATEGY -- Tenth company sourced by firm’s European team in the past five years -- -- Developing first ever therapy targeting the tumor suppressing protein

First Page		Document Content
Date: 2016-03-09 17:09:48 HealthCap Versant Chemotherapy		VERSANT VENTURES BACKS APREA AB CONTINUING GLOBAL INVESTMENT STRATEGY -- Tenth company sourced by firm’s European team in the past five years -- -- Developing first ever therapy targeting the tumor suppressing protein Add to Reading List Source URL: www.versantventures.com Download Document from Source Website File Size: 46,51 KB Share Document on Facebook

	PDF Document DocID: 1xtWO - View Document
	PDF Document DocID: 1wp9v - View Document
	#4503 A Small Molecule Glycomimetic Antagonist of E-selectin (GMIPrevents Pancreatic Tumor Metastasis and Offers Improved Efficacy of Chemotherapy Maria M. Steele1, BS, Prakash Radhakrishnan1, PhD, John L. Magnani DocID: 1vkKU - View Document
	chemotherapy.com www.chemotherapy.com GETTING STARTED Getting Started Questions Worksheet DocID: 1vd5Y - View Document
	TEARS FOR AN UNKNOWN SOLDIER As I watch my mother try to come to terms with the news that she has cancer for the third time and the look of trepidation on her face when she hears that chemotherapy will be required one mo DocID: 1v7Eu - View Document